JAK1 and neoplasm: Several in vivo pre-clinical models and CRISPR screens support this observation, as cell lines with mutations in IFNγR or downstream signalling molecules such as JAK1/2 and STAT1 have been shown to sensitise the tumour towards improved ICB response23,24.